Cell therapies have the potential to transform outcomes across multiple diseases, but the path from promising preclinical results to a viable clinical-stage therapy is rarely straightforward. Researchers developing these treatments face multiple scientific, technical, and regulatory hurdles when translating early-stage discoveries into treatments that can reach patients.
In this webinar, brought to you by ACROBiosystems, researchers at the forefront of cell therapy development will share their firsthand insights into the path from bench to bedside, including scale-up, analytical development, and navigating regulatory requirements.
Natalie Francis from King’s College London will discuss the development of a pluripotent stem cell therapy designed to treat retinal degeneration through a gene-agnostic approach, offering hope for patients who have already experienced significant vision loss.
Dominik Schmiedel from the Fraunhofer Institute for Cell Therapy and Immunology (IZI) will present a platform for engineering natural killer (NK) cells to express defined TCR-CD3 complexes, enabling an off-the-shelf approach to targeting intracellular antigens in infectious disease and cancer.
Topics to be covered in this webinar
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.